CPHI 2024 Speaker and End-to-End Biologics Business Development Consultant. In my role, I lead engagements with clients, understanding their unique needs, and delivering innovative solutions that optimize efficiency and accelerate time to market. My primary focus is building strategic relationships with pharmaceutical companies seeking a reliable partner to navigate the complexities of biopharma. I am helped tremendously by my experience from the Research & Development Department, where I participated in the transfer of analytical methods within the framework of a cooperation project with Novavax Inc. for the production of the COVID-19 vaccine. Thanks to the working with a fully professional team, I became thoroughly familiar with the analytical methods used in the analysis of monoclonal antibodies (rituximab, cetuximab) and the Nuvaxovid vaccine. By harnessing our CDMO's expertise in all stages of biologic drug development, I help transform concepts into tangible, life-changing therapies for patients in need.